Lansdowne et al. in £25m series-B for Genomics

US-based drug developer Vertex Pharmaceuticals led the funding round. Other participating investors included listed tech investor IP Group, asset managers Woodford Investment Management and Invesco Perpetual, Oxford University spinouts incubator Oxford Sciences Innovation, investment firm Lansdowne Partners and Tanarra.

With the new funding, Genomics will expand to enhance its database and to pursue opportunities that emerge in its market space.

Additionally, Genomics will use the fresh capital to collaborate with Vertex, in order to advance Vertex's efforts to develop transformative medicines for people with serious diseases.

Company
Founded in 2014 and headquartered in Oxford, Genomics is a genome analysis company. It has developed an analysis engine that uses genetics to understand human biology and the likely efficacy and safety of potential novel medicines. Genomics has a cross-disciplinary team of 40 people, primarily scientists and software engineers, with offices in Oxford and Cambridge.

People
Genomics – Peter Donnelly (founder, CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• United Kingdom
• Venture